RAD23B

Across TCGA pan-cancer cohorts, RAD23B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAD23B data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RAD23B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAD23B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, ESCA, and STAD are the cancer types where RAD23B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.299	0.693	.001	36	view →
ESCA	DFS	Median	All	0.119	0.536	<.001	18	view →
STAD	DFS	Median	All	0.149	0.710	<.001	15	view →
UCEC	DFS	Median	All	1.000	0.624	.005	14	view →
HNSC	OS	Median	All	0.425	0.770	.022	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAD23B–OV (OS)

Open the OV breakdown →